Executive interview – ROVI

Published on 6 March 2019

Laboratorios Farmacéuticos ROVI is a fully integrated, profitable Spanish pharmaceutical company established in 1946 that listed on the Madrid Stock Exchange in 2007. ROVI is involved in the research and development, in-licensing, manufacture and marketing of small-molecule and speciality biologic drugs. It has a particular expertise in low molecular weight heparins (LMWH), with internally developed assets Hibor (bemiparin) and Becat (enoxaparin biosimilar) the key drivers of near-term revenue and profit growth. Sustainable long-term growth is dependent on successful R&D investment and ROVI’s efforts here lie in its in situ microimplant (ISM) technology. In this video, the company’s vice president and chief financial officer Javier López-Belmonte introduces the company and its LMWH franchise then gives an overview of the commercialisation strategy for its Phase III asset, DORIA (risperidone ISM). Read more on ROVI>>

Share this with friends and colleagues